Table 2A.

Characteristics of patients who are alive after transplantation

Age at diagnosis	Age at transplant	Year of transplant	Donor source	Conditioning regimen	GVHD	Time to last contact	Status
7.7 years	18.0 years	1992	HLA-matched sibling	Busulfan + cyclophosphamide	Chronic	114.3 months	Alive
15.0 years	18.5 years	1997	HLA-matched sibling	Cyclophosphamide	Chronic	73 months	Alive
11.1 years	17.6 years	2000	HLA-matched sibling	Cyclophosphamide	None	82.2 months	Alive
19.4 years	21.7 years	2001	HLA-matched sibling	Cyclophosphamide	None	115.7 months	Alive
9.0 years	13.3 years	2006	Matched unrelated donor*	Melphalan + fludarabine	None	59.6 months	Alive
6.5 years	6.8 years	2007	HLA-matched sibling	Cyclophosphamide	Chronic	49.1 months	Alive
24.7 years	35.1 years	2007	Matched unrelated donor*	Busulfan + fludarabine	Chronic	60.4 months	Alive
6.6 years	13.7 years	2008	HLA-matched sibling*	Cyclophosphamide	None	3.32 months	Alive
1.1 years	3.2 years	2008	Matched unrelated donor	TBI 200 cGy + fludarabine	None	29.2 months	Alive
4.3 years	4.7 years	2008	Matched unrelated donor	Cyclophosphamide fludarabine	None	38.7 months	Alive
4.1 years	9.4 years	2008	Matched unrelated donor	TBI 200 cGy + fludarabine	Chronic	39.8 months	Alive
1.7 years	2.3 years	2008	Matched unrelated donor	Cyclophosphamide	Chronic	43.2 months	Alive
19.4 years	19.9 years	2009	HLA-matched sibling*	Cyclophosphamide + fludarabine	Acute	12.5 months	Alive
4.4 years	4.8 years	2009	HLA-matched sibling	Unknown	None	37.4 months	Alive

^*peripheral blood progenitor cells; others received bone marrow